Therapeutics - RA 3

Card Set Information

Author:
kyleannkelsey
ID:
282086
Filename:
Therapeutics - RA 3
Updated:
2014-09-04 13:09:04
Tags:
Therapeutics RA
Folders:
Therapeutics - RA 3
Description:
Therapeutics - RA 3
Show Answers:

Home > Flashcards > Print Preview

The flashcards below were created by user kyleannkelsey on FreezingBlue Flashcards. What would you like to do?


  1. The patient has failed on Hydroxychloroquine if no symptom relief has developed in _________.
    6 months
  2. What is the main advantage of Hydroxychloroquine?
    No myelosupression, hepatic or renal toxicities
  3. What are the adverse effects of Hydroxychloroquine?
    • GI distress
    • Ocular toxicities
    • Dermatologic
    • Neurologic
  4. What clinical monitoring is needed with Hydroxychloroquine treatment?
    • Baseline eye exam
    • Opthalmoscopy every 9-12 months for vision changes
  5. What is the Amsler grid?
    A grid used to test for ocular issues associated with Hydroxychloroquine use
  6. What is the usual dose for Sulfasalazine?
    • 500 mg PO BID
    • Titrate to 100 mg PO BID
  7. What is the onset of symptom relief for Sulfasalazine?
    2months
  8. Sulfasalazine is a prodrug cleaved in the intestines, what is the active form?
    • Sulfapyridine
    • 5-aminosalicylic acid
  9. Sulfasalazine has higher concentrations in certain tissues what are they?
    • Serous fluid
    • Liver
    • Intestines
  10. Does Sulfasalazine slow radiographic progression?
    Yes
  11. What are the AE of Sulfasalazine?
    • GI
    • Dermatologic
    • Leukopenia
    • Hepatitis
  12. How should you monitor Sulfasalazine?
    CBC, AST and ALT
  13. What DDIs does Sulfasalazine have?
    • Warfarin is displaced from protein by sulfasalazine
    • Antibiotics can thwart prodrug activation in the intestines
    • Iron chelates Sulfasalazine and decrease its absorption
  14. TNF-alpha Biologics should be avoided with what concomitant disease state?
    • Stage 3 or 4 HF
    • Caution with stage 1 or 2
  15. What are the main risks of all Biologic DMARDs?
    • Infection
    • Malignancy
    • HF (TNF-alpha inhibitors)
  16. Why should you not use Biologic DMARDs in people with recent cancer?
    They block anti-cancer molecules and may cause malignancy
  17. Infliximab produces symptom relief for RA in what time period?
    3-7 days
  18. Adalimumab produces symptom relief for RA in what time period?
    3 months
  19. Can you combine TNF-alpha inhibitors with methotrexate?
    Yes
  20. Can you combine TNF-alpha inhibitors with other biologic DMARDs?
    No

What would you like to do?

Home > Flashcards > Print Preview